Intrauterine Environment and Polycystic Ovary Syndrome

Abstract

The maternal–fetal environment plays an important role in developmental programming of adult disease. Metabolic and hormonal dysfunction during human fetal development accompanies gestational diabetes as a common occurrence in mothers with polycystic ovary syndrome (PCOS), while human fetal androgen excess from congenital adrenal hyperplasia or virilizing tumors precedes PCOS-like symptoms after birth. To date, clinical studies of infant blood levels at term have yet to confirm that human fetal androgen excess promotes PCOS development after birth. Earlier in development, however, circulating androgen levels in the second trimester female human fetus can normally rise into the male range. Furthermore, midgestational amniotic testosterone levels are elevated in female fetuses of PCOS compared with normal mothers and might influence fetal development because experimentally induced fetal androgen excess in animals produces a PCOS-like phenotype with reproductive and metabolic dysfunction. Such alterations in the maternal–fetal environment likely program adult PCOS by epigenetic modifications of genetic susceptibility of the fetus to PCOS after birth. Understanding this phenomenon requires advanced fetal surveillance technologies and postnatal assessment of midgestational androgen exposure for new clinical strategies to improve reproduction in PCOS women, optimize long-term health of their offspring, and minimize susceptibility to acquiring PCOS in future generations.

Keywords

polycystic ovary syndrome - hyperandrogenism - hyperinsulinemia - adiposity - developmental programming - fetal development

• References

• 1 Zawadzki J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, , eds. Polycystic Ovary Syndrome. Boston, MA: Blackwell Scientific; 1992: 377-384
• 2 Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab 2005; 90 (8) 4650-4658
• 3 Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19 (1) 41-47
• 4 Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89 (6) 2745-2749
• 5 Fauser BCJM, Tarlatzis BC, Rebar RW , et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012; 97 (1) 28-38 , e25
• 6 March WA, Moore VM, Willson KJ, Phillips DIW, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25 (2) 544-551
• 7 Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab 2005; 90 (5) 2545-2549
• 8 Welt CK, Gudmundsson JA, Arason G , et al. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab 2006; 91 (12) 4842-4848
• 9 Azziz R, Carmina E, Dewailly D , et al; Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006; 91 (11) 4237-4245
• 10 Barnes RB, Rosenfield RL, Ehrmann DA , et al. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab 1994; 79 (5) 1328-1333
• 11 Merke DP, Cutler Jr GB. New ideas for medical treatment of congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2001; 30 (1) 121-135
• 12 Phocas I, Chryssikopoulos A, Sarandakou A, Rizos D, Trakakis E. A contribution to the classification of cases of non-classic 21-hydroxylase-deficient congenital adrenal hyperplasia. Gynecol Endocrinol 1995; 9 (3) 229-238
• 13 Stikkelbroeck NM, Hermus AR, Braat DD, Otten BJ. Fertility in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Obstet Gynecol Surv 2003; 58 (4) 275-284
• 14 Dumesic DA, Abbott DH, Padmanabhan V. Polycystic ovary syndrome and its developmental origins. Rev Endocr Metab Disord 2007; 8: 127-141
• 15 Kuijper EAM, Vink JM, Lambalk CB, Boomsma DI. Prevalence of polycystic ovary syndrome in women from opposite-sex twin pairs. J Clin Endocrinol Metab 2009; 94 (6) 1987-1990
• 16 Cattrall FR, Vollenhoven BJ, Weston GC. Anatomical evidence for in utero androgen exposure in women with polycystic ovary syndrome. Fertil Steril 2005; 84 (6) 1689-1692
• 17 Palomba S, Marotta R, Di Cello A , et al. Pervasive developmental disorders in children of hyperandrogenic women with polycystic ovary syndrome: a longitudinal case-control study. Clin Endocrinol (Oxf) 2012; 77 (6) 898-904
• 18 Lujan ME, Bloski TG, Chizen DR, Lehotay DC, Pierson RA. Digit ratios do not serve as anatomical evidence of prenatal androgen exposure in clinical phenotypes of polycystic ovary syndrome. Hum Reprod 2010; 25 (1) 204-211
• 19 Lujan ME, Podolski AJ, Chizen DR, Lehotay DC, Pierson RA. Digit ratios by computer-assisted analysis confirm lack of anatomical evidence of prenatal androgen exposure in clinical phenotypes of polycystic ovary syndrome. Reprod Biol Endocrinol 2010; 8: 156-163
• 20 Lutchmaya S, Baron-Cohen S, Raggatt P, Knickmeyer R, Manning JT. 2nd to 4th digit ratios, fetal testosterone and estradiol. Early Hum Dev 2004; 77 (1–2) 23-28
• 21 Abbott AD, Colman RJ, Tiefenthaler R, Dumesic DA, Abbott DH. Early-to-mid gestation fetal testosterone increases right hand 2D:4D finger length ratio in polycystic ovary syndrome-like monkeys. PLoS ONE 2012; 7 (8) e42372
• 22 Barry JA, Kay AR, Navaratnarajah R , et al. Umbilical vein testosterone in female infants born to mothers with polycystic ovary syndrome is elevated to male levels. J Obstet Gynaecol 2010; 30 (5) 444-446
• 23 Mehrabian F, Kelishadi R. Comparison of the metabolic parameters and androgen level of umbilical cord blood in newborns of mothers with polycystic ovary syndrome and controls. J Res Med Sci 2012; 17 (3) 207-211
• 24 Anderson H, Fogel N, Grebe SK, Singh RJ, Taylor RL, Dunaif A. Infants of women with polycystic ovary syndrome have lower cord blood androstenedione and estradiol levels. J Clin Endocrinol Metab 2010; 95 (5) 2180-2186
• 25 Maliqueo M, Lara HE, Sánchez F, Echiburú B, Crisosto N, Sir-Petermann T. Placental steroidogenesis in pregnant women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2013; 166 (2) 151-155
• 26 Hickey M, Sloboda DM, Atkinson HC , et al. The relationship between maternal and umbilical cord androgen levels and polycystic ovary syndrome in adolescence: a prospective cohort study. J Clin Endocrinol Metab 2009; 94 (10) 3714-3720
• 27 Cole B, Hensinger K, Maciel GAR, Chang RJ, Erickson GF. Human fetal ovary development involves the spatiotemporal expression of p450c17 protein. J Clin Endocrinol Metab 2006; 91 (9) 3654-3661
• 28 Mesiano S. The endocrinology of human pregnancy and fetoplacental neuroendocrine development. In: Strauss III JF, Barbieri RL, , eds. Yen and Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management. 6th ed. Philadelphia, PA: Saunders Elsevier; 2009: 248-281
• 29 Fowler PA, Anderson RA, Saunders PT , et al. Development of steroid signaling pathways during primordial follicle formation in the human fetal ovary. J Clin Endocrinol Metab 2011; 96 (6) 1754-1762
• 30 van de Beek C, Thijssen JHH, Cohen-Kettenis PT, van Goozen SHM, Buitelaar JK. Relationships between sex hormones assessed in amniotic fluid, and maternal and umbilical cord serum: what is the best source of information to investigate the effects of fetal hormonal exposure?. Horm Behav 2004; 46 (5) 663-669
• 31 Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 2011; 7 (4) 219-231
• 32 Adashi EY. The ovarian follicular apparatus. In: Adashi EY, Rock JA, Rosenwaks Z, , eds. Reproductive Endocrinology, Surgery, and Technology. Philadelphia, PA: Lippincott-Raven; 1996: 18-40
• 33 Hatzirodos N, Bayne RA, Irving-Rodgers HF , et al. Linkage of regulators of TGF-β activity in the fetal ovary to polycystic ovary syndrome. FASEB J 2011; 25 (7) 2256-2265
• 34 Voutilainen R, Miller WL. Developmental expression of genes for the stereoidogenic enzymes P450scc (20,22-desmolase), P450c17 (17 alpha-hydroxylase/17,20-lyase), and P450c21 (21-hydroxylase) in the human fetus. J Clin Endocrinol Metab 1986; 63 (5) 1145-1150
• 35 Shifren JL, Osathanondh R, Yeh J. Human fetal ovaries and uteri: developmental expression of genes encoding the insulin, insulin-like growth factor I, and insulin-like growth factor II receptors. Fertil Steril 1993; 59 (5) 1036-1040
• 36 Payne AH, Jaffe RB. Androgen formation from pregnenolone sulfate by the human fetal ovary. J Clin Endocrinol Metab 1974; 39 (2) 300-304
• 37 Wilson EA, Jawad MJ. The effect of trophic agents on fetal ovarian steroidogenesis in organ culture. Fertil Steril 1979; 32 (1) 73-79
• 38 George FW, Wilson JD. Conversion of androgen to estrogen by the human fetal ovary. J Clin Endocrinol Metab 1978; 47 (3) 550-555
• 39 Pepe GJ, Billiar RB, Albrecht ED. Regulation of baboon fetal ovarian folliculogenesis by estrogen. Mol Cell Endocrinol 2006; 247 (1–2) 41-46
• 40 Albrecht ED, Pepe GJ. Estrogen regulation of placental angiogenesis and fetal ovarian development during primate pregnancy. Int J Dev Biol 2010; 54 (2–3) 397-408
• 41 Reyes FI, Winter JS, Faiman C. Studies on human sexual development. I. Fetal gonadal and adrenal sex steroids. J Clin Endocrinol Metab 1973; 37 (1) 74-78
• 42 Beck-Peccoz P, Padmanabhan V, Baggiani AM , et al. Maturation of hypothalamic-pituitary-gonadal function in normal human fetuses: circulating levels of gonadotropins, their common alpha-subunit and free testosterone, and discrepancy between immunological and biological activities of circulating follicle-stimulating hormone. J Clin Endocrinol Metab 1991; 73 (3) 525-532
• 43 Barbieri RL, Saltzman DH, Torday JS, Randall RW, Frigoletto FD, Ryan KJ. Elevated concentrations of the β-subunit of human chorionic gonadotropin and testosterone in the amniotic fluid of gestations of diabetic mothers. Am J Obstet Gynecol 1986; 154 (5) 1039-1043
• 44 Driscoll SG, Benirschke K, Curtis GW. Neonatal deaths among infants of diabetic mothers. Postmortem findings in ninety-five infants. Am J Dis Child 1960; 100: 818-835
• 45 Hultquist GT, Olding LB. Endocrine pathology of infants of diabetic mothers. A quantitative morphological analysis including a comparison with infants of iso-immunized and of non-diabetic mothers. Acta Endocrinol Suppl (Copenh) 1981; 241 (Suppl): 1-202
• 46 Sir-Petermann T, Maliqueo M, Angel B, Lara HE, Pérez-Bravo F, Recabarren SE. Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization. Hum Reprod 2002; 17 (10) 2573-2579
• 47 Boomsma CM, Eijkemans MJC, Hughes EG, Visser GHA, Fauser BCJM, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006; 12 (6) 673-683
• 48 Kjerulff LE, Sanchez-Ramos L, Duffy D. Pregnancy outcomes in women with polycystic ovary syndrome: a metaanalysis. Am J Obstet Gynecol 2011; 204: 1-6
• 49 Altieri P, Gambineri A, Prontera O, Cionci G, Franchina M, Pasquali R. Maternal polycystic ovary syndrome may be associated with adverse pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol 2010; 149 (1) 31-36
• 50 Bjercke S, Dale PO, Tanbo T, Storeng R, Ertzeid G, Abyholm T. Impact of insulin resistance on pregnancy complications and outcome in women with polycystic ovary syndrome. Gynecol Obstet Invest 2002; 54 (2) 94-98
• 51 Abbott DH, Bruns CR, Barnett DK , et al. Experimentally-induced gestational androgen excess disrupts glucoregulation in rhesus monkey dams and their female offspring. Am J Physiol Endocrinol Metab 2010; 299: E741-E751
• 52 Padmanabhan V, Veiga-Lopez A. Developmental origin of reproductive and metabolic dysfunctions: androgenic versus estrogenic reprogramming. Semin Reprod Med 2011; 29 (3) 173-186
• 53 Sir-Petermann T, Codner E, Maliqueo M , et al. Increased anti-Müllerian hormone serum concentrations in prepubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91 (8) 3105-3109
• 54 Crisosto N, Echiburú B, Maliqueo M , et al. Improvement of hyperandrogenism and hyperinsulinemia during pregnancy in women with polycystic ovary syndrome: possible effect in the ovarian follicular mass of their daughters. Fertil Steril 2012; 97 (1) 218-224
• 55 Maliqueo M, Echiburú B, Crisosto N , et al. Metabolic parameters in cord blood of newborns of women with polycystic ovary syndrome. Fertil Steril 2009; 92 (1) 277-282
• 56 Crisosto N, Codner E, Maliqueo M , et al. Anti-Müllerian hormone levels in peripubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92 (7) 2739-2743
• 57 Kent SC, Gnatuk CL, Kunselman AR, Demers LM, Lee PA, Legro RS. Hyperandrogenism and hyperinsulinism in children of women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 2008; 93 (5) 1662-1669
• 58 Sir-Petermann T, Codner E, Pérez V , et al. Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009; 94 (6) 1923-1930
• 59 Yamamoto M, Feigenbaum SL, Crites Y , et al. Risk of preterm delivery in non-diabetic women with polycystic ovarian syndrome. J Perinatol 2012; 32 (10) 770-776
• 60 Cresswell JL, Barker DJ, Osmond C, Egger P, Phillips DI, Fraser RB. Fetal growth, length of gestation, and polycystic ovaries in adult life. Lancet 1997; 350 (9085) 1131-1135
• 61 Mumm H, Kamper-Jørgensen M, Nybo Andersen AM, Glintborg D, Andersen M. Birth weight and polycystic ovary syndrome in adult life: a register-based study on 523,757 Danish women born 1973-1991. Fertil Steril 2013; 99 (3) 777-782
• 62 Sir-Petermann T, Hitchsfeld C, Maliqueo M , et al. Birth weight in offspring of mothers with polycystic ovarian syndrome. Hum Reprod 2005; 20 (8) 2122-2126
• 63 Ibáñez L, Potau N, Francois I, de Zegher F. Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J Clin Endocrinol Metab 1998; 83 (10) 3558-3562
• 64 Legro RS, Roller RL, Dodson WC, Stetter CM, Kunselman AR, Dunaif A. Associations of birthweight and gestational age with reproductive and metabolic phenotypes in women with polycystic ovarian syndrome and their first-degree relatives. J Clin Endocrinol Metab 2010; 95 (2) 789-799
• 65 Laitinen J, Taponen S, Martikainen H , et al. Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms. Int J Obes Relat Metab Disord 2003; 27 (6) 710-715
• 66 Haakova L, Cibula D, Rezabek K, Hill M, Fanta M, Zivny J. Pregnancy outcome in women with PCOS and in controls matched by age and weight. Hum Reprod 2003; 18 (7) 1438-1441
• 67 Mikola M, Hiilesmaa V, Halttunen M, Suhonen L, Tiitinen A. Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod 2001; 16 (2) 226-229
• 68 Chazenbalk GD, Aguilera P, Keller E, Dumesic DA, Abbott DH. Altered transition of adipose stem cell commitment to early preadipocyte differentiation in subcutaneous abdominal adipose tissue of adult PCOS-like female rhesus monkeys. Paper presented at the 95th Annual Meeting of the Endocrine Society; June 15–18, 2013; San Francisco, CA, Poster Mon-555
• 69 Chazenbalk G, Singh P, Irge D, Shah A, Abbott DH, Dumesic DA. Androgens inhibit adipogenesis during human adipose stem cell commitment to preadipocyte formation. Steroids 2013; 78 (9) 920-926
• 70 Heneidi S, Simerman AA, Keller E , et al. Awakened by cellular stress: isolation and characterization of a novel population of pluripotent stem cells derived from human adipose tissue. PLoS ONE 2013; 8 (6) e64752
• 71 Legro RS, Driscoll D, Strauss III JF, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A 1998; 95 (25) 14956-14960
• 72 Kahsar-Miller MD, Nixon C, Boots LR, Go RC, Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril 2001; 75 (1) 53-58
• 73 Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab 2006; 91 (6) 2100-2104
• 74 Chen ZJ, Zhao H, He L , et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet 2011; 43 (1) 55-59
• 75 Shi Y, Zhao H, Shi Y , et al. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat Genet 2012; 44 (9) 1020-1025
• 76 Zeggini E, Scott LJ, Saxena R , et al; Wellcome Trust Case Control Consortium. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 2008; 40 (5) 638-645
• 77 Voight BF, Scott LJ, Steinthorsdottir V , et al; MAGIC investigators; GIANT Consortium. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010; 42 (7) 579-589
• 78 Hakonarson H, Qu HQ, Bradfield JP , et al. A novel susceptibility locus for type 1 diabetes on Chr12q13 identified by a genome-wide association study. Diabetes 2008; 57 (4) 1143-1146
• 79 Lango Allen H, Estrada K, Lettre G , et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 2010; 467 (7317) 832-838
• 80 Fox CS, Heard-Costa N, Cupples LA, Dupuis J, Vasan RS, Atwood LD. Genome-wide association to body mass index and waist circumference: the Framingham Heart Study 100K project. BMC Med Genet 2007; 8 (Suppl. 01) S18
• 81 Díaz-Perales A, Quesada V, Sánchez LM , et al. Identification of human aminopeptidase O, a novel metalloprotease with structural similarity to aminopeptidase B and leukotriene A4 hydrolase. J Biol Chem 2005; 280 (14) 14310-14317
• 82 Li Z, Huang H. Epigenetic abnormality: a possible mechanism underlying the fetal origin of polycystic ovary syndrome. Med Hypotheses 2008; 70 (3) 638-642
• 83 Zhu JQ, Zhu L, Liang XW, Xing FQ, Schatten H, Sun QY. Demethylation of LHR in dehydroepiandrosterone-induced mouse model of polycystic ovary syndrome. Mol Hum Reprod 2010; 16 (4) 260-266
• 84 Qu F, Wang FF, Yin R , et al. A molecular mechanism underlying ovarian dysfunction of polycystic ovary syndrome: hyperandrogenism induces epigenetic alterations in the granulosa cells. J Mol Med (Berl) 2012; 90 (8) 911-923
• 85 Xu N, Kwon S, Abbott DH , et al. Epigenetic mechanism underlying the development of polycystic ovary syndrome (PCOS)-like phenotypes in prenatally androgenized rhesus monkeys. PLoS ONE 2011; 6 (11) e27286
• 86 Dos Santos E, Dieudonné MN, Leneveu MC, Pecquery R, Serazin V, Giudicelli Y. In vitro effects of chorionic gonadotropin hormone on human adipose development. J Endocrinol 2007; 194 (2) 313-325
• 87 Park BH, Kim YJ, Park JS , et al. Folate and homocysteine levels during pregnancy affect DNA methylation in human placenta [in Korean]. J Prev Med Pub Health 2005; 38 (4) 437-442
• 88 Rees WD, Wilson FA, Maloney CA. Sulfur amino acid metabolism in pregnancy: the impact of methionine in the maternal diet. J Nutr 2006; 136 (6, Suppl): 1701S-1705S
• 89 Kwong WY, Miller DJ, Wilkins AP , et al. Maternal low protein diet restricted to the preimplantation period induces a gender-specific change on hepatic gene expression in rat fetuses. Mol Reprod Dev 2007; 74 (1) 48-56